Publications
Latest News, Publications, Events & Insights
Stay up to date with Clinical Trial Ranking Report's latest press releases, peer-reviewed publications, case studies, and conference presentations.
Scipher Medicine Expands Dx Focus to Data- Driven Precision Medicine Development
NEW YORK – After about a year under new leadership, Scipher Medicine, which developed and markets one of the only molecular assays to aid treatment decisions in rheumatoid arthritis, is making progress in its attempt to advance personalized medicine across a variety of non-oncology disease areas.
Molecular testing in cancer patients has led to the identification of target pathways for a growing class of drugs, as well as a host of biomarkers that can predict which patients will respond to certain therapies.
A Network-Based Framework to Discover Treatment-ResponseePredicting Biomarkers for Complex Diseases.
The potential of precision medicine to transform complex autoimmune disease treatment is often challenged by limited data availability and inadequate sample size when compared with the number of molecular features found in high-throughput multi-omics data sets. To address this issue, the novel framework PRoBeNet (Predictive Response Biomarkers using Network medicine) was developed.
The module triad: a novel network biology approach to utilize patients’ multi‐omics data for target discovery in ulcerative colitis.
Tumor necrosis factor-α inhibitors (TNFi) have been a standard treatment in ulcerative colitis (UC) for nearly 20 years. However, insufficient response rate to TNFi therapies along with concerns around their immunogenicity and inconvenience of drug delivery through injections calls for development of UC drugs targeting alternative proteins.